Meliglix

Sitagliptin, the active ingredient in Meliglix, is a dipeptidyl peptidase‑4 (DPP‑4) inhibitor presented as an oral tablet for oral use. It is used to improve blood glucose control in adults with type 2 diabetes mellitus, typically as an adjunct to diet and exercise.

GNH USA supplies Meliglix as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Meliglix (sitagliptin) belongs to the DPP‑4 inhibitor class and is employed in the management of type 2 diabetes mellitus. - Type 2 diabetes mellitus: improves glycemic control when combined with diet and exercise. - Monotherapy in patients inadequately controlled by lifestyle alone: provides additional glucose lowering. - Combination therapy with other antidiabetic agents: enhances overall blood sugar management.

Adverse reactions to sitagliptin are generally mild to moderate, but serious events can occur and require prompt medical attention.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Headache: transient cranial discomfort. - Nasopharyngitis: common cold‑like symptoms. - Upper respiratory tract infection: mild cough or sore throat. - Dizziness: occasional light‑headedness. - Hypoglycaemia (when used with insulin or sulfonylureas): low blood sugar episodes.

Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain requiring urgent care. - Severe allergic reactions: rash, angioedema, or anaphylaxis. - Bullous pemphigoid: blistering skin disorder. - Hepatic injury: elevated liver enzymes or jaundice. - Severe joint pain: unexplained arthralgia.

Before initiating sitagliptin therapy, several safety considerations should be reviewed. - Renal impairment: dose adjustment may be required based on creatinine clearance. - Hepatic disease: monitor liver function tests regularly. - History of pancreatitis: avoid use due to potential recurrence. - Elderly patients: observe for signs of hypoglycaemia, especially when combined with other agents. - Pregnancy and lactation: safety not established; use only if clearly needed. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Sitagliptin may interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Insulin: increased risk of hypoglycaemia. - Sulfonylureas (e.g., glipizide): heightened hypoglycaemia potential.

Moderate Interactions (Monitor Closely): - Rifampin: may reduce sitagliptin plasma concentrations. - Diuretics (e.g., furosemide): can increase serum creatinine. - ACE inhibitors (e.g., lisinopril): monitor renal function and electrolytes.